Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
SEC Accession No. 0000897069-25-000852
Filing Date
2025-04-23
Accepted
2025-04-23 17:29:15
Documents
23

Document Format Files

Seq Description Document Type Size
1 schedule14a.htm DFAN14A 19649
2 image0.jpg GRAPHIC 338781
3 image1.jpg GRAPHIC 367219
4 image2.jpg GRAPHIC 346660
5 image3.jpg GRAPHIC 622461
6 image4.jpg GRAPHIC 217405
7 image5.jpg GRAPHIC 201846
8 image6.jpg GRAPHIC 395570
9 image7.jpg GRAPHIC 238778
10 image8.jpg GRAPHIC 213187
11 image9.jpg GRAPHIC 241997
12 image10.jpg GRAPHIC 612608
13 image11.jpg GRAPHIC 336678
14 image12.jpg GRAPHIC 286673
15 image13.jpg GRAPHIC 287115
16 image14.jpg GRAPHIC 556326
17 image15.jpg GRAPHIC 425139
18 image16.jpg GRAPHIC 435249
19 image17.jpg GRAPHIC 151703
20 image18.jpg GRAPHIC 395917
21 image19.jpg GRAPHIC 660442
22 image20.jpg GRAPHIC 260456
23 image21.jpg GRAPHIC 447479
  Complete submission text file 0000897069-25-000852.txt   11095762
Mailing Address 1180 CELEBRATION BOULEVARD, SUITE 103 CELEBRATION FL 34747
Business Address 1180 CELEBRATION BOULEVARD, SUITE 103 CELEBRATION FL 34747 (321) 939-3416
ZEVRA THERAPEUTICS, INC. (Subject) CIK: 0001434647 (see all company filings)

EIN.: 205894398 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DFAN14A | Act: 34 | File No.: 001-36913 | Film No.: 25862816
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 2146 SWANSTONE CIRCLE DE PERE WI 54115
Business Address
Mangless Daniel John (Filed by) CIK: 0001779475 (see all company filings)

Type: DFAN14A